Raven StealthCo - Principal Scientist, In Vivo Pharmacology

About Raven:

We are Raven, RA Capital’s healthcare incubator. From discovery to delivery, whether we incubate, accelerate or rejuvenate, Raven’s goal is to turn scientific breakthroughs into transformative therapies and get them quickly, safely and efficiently to the patients that need them most. Raven’s experienced scientists, operators, and healthcare innovators have deep sector expertise across therapeutics, diagnostics, devices and services. They have brought hundreds of therapeutics into development, managed hospital systems, optimized clinical trials and navigated payor and regulatory systems to deliver patient impact - and they are ready to work with you.

Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow‑on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our Tech Atlas internal research division, and Raven, RA Capital’s company building team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re‑imagined.

RA Capital has more than 150 employees and over $10 billion in assets under management.

We are a well‑funded, stealth‑mode biotechnology focused on next generation oligo‑based modalities targeting tissues beyond the liver, muscle, and kidney. We are buildinga platform to deliver oligos with high precision to previously untargeted cells, while focused on "undruggable" genes, alone or in combination with previously validated targets. Many of our targets carry "pipeline-in-a-drug" potential: a single gene or protein with meaningful biological effects across multiple disease areas.

Headquartered in Cambridge, Massachusetts, the company was incubated in RA Capital’s venture group (Raven) and is led by an experienced CEO. After a robust incubation and vetting process, Raven Stealth Co was launched and funded by RA Capital. The company’s therapeutic areas of interest lie outside commonly targeted cells and tissues, and represent multi‑billion‑dollar markets that are continuing to grow as the population ages.

Our initial focus is creating transformational therapies to treatdiseases, but given the platform potential, we have longer‑term ambitions to addresshealthy aging. These targets are backed by strong biological and genetic evidence buthave historically resisted small molecule and biologic approaches. Raven Stealth Co ismoving quickly to address multiple disease indications at scale and with significantmarket potential.

We are in the discovery stage and will invest heavily in our emerging platform for oligonucleotide delivery. Our disease focus is supported by highly predictive animal models with strong translatability to humans, offering a potentially rapid and efficient path to the clinic. Given our recent funding and commitment to building a first‑in‑class platform, we are recruiting a Principal Scientist / Associate Director, In Vivo Pharmacology to design, manage, and interpret the externally executed studies that establish pharmacokinetics, target engagement, pharmacodynamics, and efficacy for our programs.

The Principal Scientist reports to the Director of Biology and Pharmacology and leads the company’s in vivo pharmacology efforts, owning how studies are designed, run, and analyzed. Working in close partnership with the Director, who sets the overall biology and pharmacology strategy in accordance with the company goals and broad scientific strategy, this person translates that strategy into a rigorous in vivo program and drives it end to end.

In vivo studies will be run externally at contract research organizations while the ex vivo analyses will be executed both internally and externally. The Principal Scientist’s focus will be the design, direction, and interpretation of that work rather than its hands‑on execution. The…